Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
- Conditions
- Schizophrenia
- Interventions
- Registration Number
- NCT04624243
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study was to evaluate the efficacy and safety of MK-8189 at a range of doses (8 mg, 16 mg, and 24 mg once daily \[QD\]) in adult participants who have an acute episode of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) criteria. The primary hypotheses were the following: (1) that MK-8189 24 mg is superior to placebo in reducing the Week 6 mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score, and (2) that MK-8189 16 mg is superior to placebo in reducing the Week 6 mean change from baseline in PANSS total score.
With Amendment 4, enrollment was changed to approximately 500 participants with removal of the MK-8189 8 mg treatment arm. Participants enrolled before Amendment 4 who were assigned to MK-8189 8 mg QD remained on that dose regimen per protocol.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 499
The main inclusion criteria include, but are not limited to the following:
- Meet the diagnostic criteria for schizophrenia according to the DSM-5
- Have an illness duration for schizophrenia of at least 1 year
- Be confirmed to be experiencing an acute episode of schizophrenia as evidenced by ALL of the following: (a) onset of the current acute episode is ≤6 weeks before screening (b) current symptoms represent a marked and substantial worsening compared with the participant's usual symptomatic state prior to the current acute episode, and are associated with diminished functional ability (c) in need of increased psychiatric attention to treat worsening acute episode symptoms
- Have a CGI-S score of ≥4 (moderately ill) at screening and baseline
- Have an identified responsible person referred to as the "external contact person" who has agreed to provide information about the participant's location if needed during outpatient portion of the study. The site personnel must consider this identified responsible person a reliable contact person, and the contact person must have regular contact with the participant (defined at screening as direct contact no fewer than 3 times per week), and with the expectation that this frequency of contact would continue (either in person or via other contact method), throughout duration of the study, including the follow-up period)
The main exclusion criteria include, but are not limited to the following:
- Has a primary current diagnosis other than schizophrenia or a comorbid diagnosis that is primarily responsible for the current symptoms and functional impairment
- Meets criteria for moderate to severe substance use disorder within past 6 months prior to screening (excluding those related to caffeine or nicotine)
- Has a known history of the following: (a) borderline personality disorder, anti-social personality disorder, or bipolar disorder (b) traumatic brain injury causing ongoing cognitive difficulties, Alzheimer's Disease, or another form of dementia, or any chronic organic disease of the central nervous system (c) intellectual disability of a severity that would impact ability to participate in the study
- Has a current diagnosis of a psychotic disorder other than schizophrenia or a behavioral disturbance thought to be due to substance abuse
- Is or was under involuntary commitment for the acute episode, because the participant is considered a danger to themselves or others
- Has a history of treatment resistance exhibited by any of the following: (a) no or minimal response to at least 2 periods of treatment lasting 6 weeks or longer, with antipsychotic agents at the maximally tolerated dose. Participants who have responded to antipsychotics only when paired with clozapine are considered treatment-resistant (b) history of electroconvulsive therapy (ECT) treatment for treatment-resistant schizophrenia within the past 6 months (c) past or current use of clozapine as single or adjunctive therapy for schizophrenia within the past 3 months
- Is currently participating in or has participated in another clinical study and received an experimental or investigational drug agent within 3 months prior to screening visit of this current study and has participated in no more than 2 studies in the past 2 years
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description MK-8189 8 mg MK-8189 Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up MK-8189 8 mg Placebo to risperidone Participants received MK-8189 8 mg QD from Weeks 1 to 12, with 2 weeks of follow-up MK-8189 16 mg MK-8189 Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up. MK-8189 16 mg Placebo to risperidone Participants received MK-8189 16 mg QD from Weeks 1 to 12, with 2 weeks of follow-up. MK-8189 24 mg MK-8189 Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up. MK-8189 24 mg Placebo to risperidone Participants received MK-8189 24 mg QD from Weeks 1 to 12, with 2 weeks of follow-up. Risperidone 6 mg Risperidone Participants will be treated for a total of 12 weeks. Participants will receive risperidone 6 mg QD in the acute treatment period from Week 1-6 followed by risperidone 6 mg QD in the extension treatment period from Week 7-12. Risperidone 6 mg Placebo to MK-8189 Participants will be treated for a total of 12 weeks. Participants will receive risperidone 6 mg QD in the acute treatment period from Week 1-6 followed by risperidone 6 mg QD in the extension treatment period from Week 7-12. Placebo and MK-8189 24 mg MK-8189 Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up. Placebo and MK-8189 24 mg Placebo to MK-8189 Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up. Placebo and MK-8189 24 mg Placebo to risperidone Participants received placebo QD from Weeks 1 to 6 and MK-8189 24 mg from Weeks 7 to 12, with 2 weeks of follow-up.
- Primary Outcome Measures
Name Time Method Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 Baseline and Week 6 The PANSS assesses the severity of schizophrenia symptoms through a 30-item clinician-rated inventory organized into a positive subscale (7 items), a negative subscale (7 items) and a general psychopathology subscale (16 items). For each item, symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme). The PANSS total score for each participant was calculated as the sum of the rating assigned to each of the 30 PANSS items, and ranges from 30 (lowest total score) to 210 (highest total score). Higher and lower change scores reflect symptom worsening and improvement, respectively. Risperidone and placebo were active and inactive controls, respectively.
Number of Participants Who Experience One or More Adverse Events (AEs) Up to Week 6 An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, events were assessed for the first 6 weeks of treatment.
Number of Participants Who Discontinued From Study Intervention Due to AE Up to Week 6 An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. Per protocol, events were assessed for the first 6 weeks of treatment.
- Secondary Outcome Measures
Name Time Method Change From Baseline in PANSS Positive Subscale (PSS) Score at Week 6 Baseline and Week 6 The PANSS Positive Subscale (PSS) assesses the severity of schizophrenia symptoms. The PANSS PSS score was calculated as the sum of the rating assigned to each of the 7 PSS items and ranges from 7 (lowest total score) to 49 (highest total score). Higher and lower change scores reflect symptom worsening and improvement, respectively. Risperidone and placebo were active and inactive controls, respectively.
Change From Baseline in Clinical Global Impression-Severity of Illness (CGI-S) Score at Week 6 Baseline and Week 6 The CGI-S is a single item 7-point clinician rated scale for assessing the global severity of the participant's illness. CGI-S scores range from 1 (participant normal, not ill) to 7 (participant extremely ill); higher and lower change from baseline scores indicate symptom worsening and improvement, respectively. Risperidone and placebo were active and inactive controls, respectively.
Change From Baseline in Body Weight at Week 12 Baseline and Week 12 The change from baseline in body weigh was determined at Week 12. Negative and positive values represent body weight loss and gain from baseline, respectively. Weight was measured using a standardized scale. Risperidone and placebo were active and inactive controls, respectively.
Change From Baseline in Body Weight at Week 6 Baseline and Week 6 The change from baseline in body weigh was determined at Week 6. Negative and positive values represent body weight loss and gain from baseline, respectively. Weight was measured using a standardized scale. Risperidone and placebo were active and inactive controls, respectively.
Change From Baseline in Body Weight at Week 12: Model-based Analysis Baseline and Week 12 The change from baseline in body weigh was determined at Week 12. Negative and positive values represent body weight loss and gain from baseline, respectively. Weight was measured using a standardized scale. Risperidone and placebo were active and inactive controls, respectively.
Change From Baseline in Body Weight at Week 6: Model-based Analysis Baseline and Week 6 The change from baseline in body weigh was determined at Week 6. Negative and positive values represent body weight loss and gain from baseline, respectively. Weight was measured using a standardized scale. Risperidone and placebo were active and inactive controls, respectively.
Trial Locations
- Locations (121)
Pillar Clinical Research ( Site 1047)
🇺🇸Bentonville, Arkansas, United States
Woodland International Research Group, LLC ( Site 1002)
🇺🇸Little Rock, Arkansas, United States
Woodland Research Northwest, LLC ( Site 1036)
🇺🇸Rogers, Arkansas, United States
CITRIALS ( Site 1010)
🇺🇸Bellflower, California, United States
ProScience Research Group ( Site 1046)
🇺🇸Culver City, California, United States
Collaborative Neuroscience Research, LLC ( Site 1041)
🇺🇸Garden Grove, California, United States
Behavioral Research Specialists, LLC ( Site 1032)
🇺🇸Glendale, California, United States
CITRIALS ( Site 1016)
🇺🇸Riverside, California, United States
Artemis Institute for Clinical Research ( Site 1019)
🇺🇸San Diego, California, United States
California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC) ( Site 103
🇺🇸San Diego, California, United States
Scroll for more (111 remaining)Pillar Clinical Research ( Site 1047)🇺🇸Bentonville, Arkansas, United States